, Tracking Stock Market Picks
Enter Symbol:
Corcept Therapeutics Incorporated (CORT) [hlAlert]

Mkt Outperform
up 142.58 %

Corcept Therapeutics Incorporated (CORT) rated Mkt Outperform with price target $8 by Rodman & Renshaw

Posted on: Thursday,  Jul 17, 2008  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Corcept Therapeutics Incorporated (NASDAQ: CORT) on 07/17/2008, when the stock price was $2.09.
Since then, Corcept Therapeutics Incorporated has gained 142.58% as of 01/15/2016's recent price of $5.07.
If you would have followed this Rodman & Renshaw's recommendation on CORT, you would have gained 142.58% of your investment in 2738 days.

Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/17/2008 8:25 AM Buy
2.09 8.00
as of 12/24/2008
1 Week down  -5.00 %
1 Month down  -13.63 %
3 Months up  10.46 %
1 YTD down  -6.86 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy